Sally Miller

Ms. Sally Miller

Dalhousie University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
SMSally Miller
Sally Miller
Robin UrquhartRobin Urquhart
Robin Urquhart
GKGeorge Kephart
George Kephart
YAYukiko Asada
Yukiko Asada
TYTallal Younis
Tallal Younis
Coordinating breast cancer treatment is a complex task that can overwhelm patients and their support networks. Though the Cancer Patient Navigator (CPN) program in Nova Scotia (NS) provides professional assistance to patients, certain groups of patients may still face barriers to accessing its services. Employing interviews and a modified Delphi approach with CPN participants, this study sought to identify factors associated with the need for navigation to help better target CPN program referrals among breast cancer patients. Six CPNs were recruited directly through the CPN program manager for interviews and surveys. The CPNs identified 27 different factors, which were divided into 4 categories: sociodemographic, psychological, clinical and health systems. While these patient factors (particularly sociodemographic) are not directly modifiable, awareness of their association with the need for navigation could be used to better target patients with a high need for navigation for referral to CPN services.

25 June 2024 in ACR Open Rheumatology
Verified
Journal Article
Open access
ZTZahi Touma
Zahi Touma
SKSheena Kayaniyil
Sheena Kayaniyil
APAnna Parackal
Anna Parackal
DBDenisse Bonilla
Denisse Bonilla
JSJiandong Su
Jiandong Su
SCShelly Chandran
Shelly Chandran
Objective: Our objective was to describe the administration of glucocorticoids (GCs) and characterize its association with organ damage in a longitudinal systemic lupus erythematosus (SLE) cohort over a time period spanning the introduction of biologics in Canada.Methods: A retrospective observational study was conducted using data from a large SLE cohort in Canada, including adults without lupus nephritis or central nervous system lupus. Patients were observed from time of entry into the cohort to the last available clinic visit (up to December 31, 2020), with a minimum of 24 months of follow‐up. Demographic and clinical characteristics, including average disease activity, treatment administration, and prevalence of organ damage, were examined. Organ damage was stratified by GC administration.Results: A total of 1,255 patients were included. The mean follow‐up duration was 10.5 (SD 8.6) years. One hundred eighty‐two (15%) patients had organ damage at baseline. More than 80% of patients were prescribed GCs over the follow‐up period, almost all patients had long‐term GC treatment, and only 5% of patients took any biologics. Organ damage was more frequent in patients with a higher average GC dose and greater years of GC exposure.Conclusion: In this large cohort of patients with SLE, the majority of patients continue to rely on GC for SLE symptom management, with limited administration of biologics. GC administration was correlated with increased irreversible organ damage. Access to novel GC‐sparing treatment options is critical to improve long‐term outcomes for patients with SLE, especially given the continued reliance on GC despite the introduction of biologics.

1 October 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
ABA Sidney Barritt
A Sidney Barritt
AQAnila Qasim
Anila Qasim
YKYestle Kim
Yestle Kim
SMSally Miller
Sally Miller
JOJohn O'DOnnell
John O'DOnnell
KJKarissa Johnston
Karissa Johnston
Aim: Metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD) are progressive liver conditions that can lead to serious long-term outcomes and adverse clinical events. Histologic liver fibrosis is an accepted short-term surrogate end point used in pivotal clinical trials supporting conditionally approved MASH therapies. This study aimed to synthesize up-to-date published associations between histologic liver fibrosis and clinical outcomes, including several novel syntheses. Materials & methods: A systematic literature review identified studies of MASH ± MASLD patients published January 2014 to November 2024 from Ovid MEDLINE ® , Embase and grey literature. Studies reporting hazard ratios (HRs) comparing the risk of relevant major adverse liver outcomes (MALO; e.g., cirrhosis, hepatic decompensation, hepatocellular carcinoma) and mortality by histologic liver fibrosis stage were included in meta-analysis. Pooled estimates were reported as HRs and 95% CIs. Results: Of 2810 returned records, there were 32 eligible studies from 39 articles. Higher fibrosis stage was associated with increased risk of clinical outcomes. Risk of progression to cirrhosis was twofold higher in F3 versus F2 (2.05 [1.45, 2.90]). Risk of hepatic decompensation was >ten-times higher in F3–4 versus F0–2 (10.93 [6.31, 18.92]). Risk of MALO and all-cause mortality were also significantly higher in F4 versus F3 and versus F2, and in F3–4 versus F0–2. Results were directionally consistent among studies of MASH-majority (≥80% MASH) populations and individually reported HRs. Conclusion: Increased clinical risk with more advanced fibrosis and/or cirrhosis among patients with significant liver disease supports the value of histologic liver fibrosis as a short-term surrogate for long-term clinical outcomes.